IOL with drug delivery devices and uninterrupted PCO barrier edge
An ophthalmic implant including an IOL with haptics, and drug delivery devices secured to the haptics. The posterior-most extent of the drug delivery device is located anterior to the posterior edge or PCE barrier edge, of the IOL. In other configurations, the drug delivery devices are provided with PCO barrier edges.
1. An ophthalmic implant comprising:
an intraocular lens (IOL) comprising an anterior side, a posterior side opposite the anterior side, a lens, a circumferential side wall circumscribing the lens, and a haptic coupled to and extending outwards from the circumferential side wall; and
a drug delivery device comprising a posterior panel comprising a posterior panel side wall, an anterior panel comprising an anterior panel side wall, a pair of posts joining the posterior panel and the anterior panel, and an aperture bounded by the posterior panel, the anterior panel, and the pair of posts, wherein the haptic is configured to be received within the aperture of the drug delivery device such that: at least a portion of the posterior panel side wall lies adjacent the circumferential side wall of the IOL; and at least a portion of the anterior panel side wall protrudes inward of the circumferential side wall of the IOL on the anterior side of the IOL.
2. The ophthalmic implant of claim 1 , wherein the anterior panel of the drug delivery device is positioned over the anterior side of the IOL at a junction of the haptic and the circumferential side wall.
3. The ophthalmic implant of claim 1 , wherein the at least a portion of the posterior panel side wall is concave in shape.
4. The ophthalmic implant of claim 1 , wherein the at least a portion of the anterior panel side wall is concave in shape.
5. The ophthalmic implant of claim 1 , wherein the anterior panel further comprises a planar anterior surface.
6. The ophthalmic implant of claim 1 , wherein the IOL and the drug delivery device are configured to be folded for positioning within an inserter for insertion into an eye of a subject.
7. The ophthalmic implant of claim 1 , wherein the anterior panel lies in a plane that is parallel to a plane of the IOL.
8. The ophthalmic implant of claim 1 , wherein the drug delivery device comprises one or more therapeutic agents dispersed within a polymer matrix.
9. The ophthalmic implant of claim 8 , wherein the one or more therapeutic agents dispersed within the polymer matrix are part of the anterior panel of the drug delivery device.
10. The ophthalmic implant of claim 8 , wherein the one or more therapeutic agents comprises a beta blocker, an alpha agonist, a ROCK Inhibitor, an adenosine receptor agonist, a carbonic anhydrase inhibitor, an adrenergic or cholinergic receptor activating agent, a prostaglandin analogue, a steroid, an aptamer, an antibody, a complement factor, an anti-oxidant, an anti-inflammatory agent, an anti-proliferative agent, an anti-mitotic agent, an antibiotic, or a combination thereof.
11. An ophthalmic implant comprising:
an intraocular lens (IOL) comprising an anterior side, a posterior side opposite the anterior side, a lens, a circumferential side wall circumscribing the lens, and a haptic coupled to and extending outwards from the circumferential side wall; and
a drug delivery device comprising an anterior panel and an attachment structure extending posteriorly from the anterior panel, the anterior panel comprising an anterior panel side wall, the attachment structure defining an aperture extending therethrough, wherein the haptic is configured to be received within the aperture of the attachment structure of the drug delivery device such that at least a portion of the anterior panel side wall protrudes inward of the circumferential side wall of the IOL on the anterior side of the IOL.
12. The ophthalmic implant of claim 11 , wherein the anterior panel of the drug delivery device is positioned over the anterior side of the IOL at a junction of the haptic and the circumferential side wall.
13. The ophthalmic implant of claim 11 , wherein the at least a portion of the anterior panel side wall is concave in shape.
14. The ophthalmic implant of claim 11 , wherein the anterior panel further comprises a planar anterior surface.
15. The ophthalmic implant of claim 11 , wherein the IOL and the drug delivery device are configured to be folded for positioning within an inserter for insertion into an eye of a subject.
16. The ophthalmic implant of claim 11 , wherein the anterior panel lies in a plane that is parallel to a plane of the IOL.
17. The ophthalmic implant of claim 11 , wherein the drug delivery device comprises one or more therapeutic agents dispersed within a polymer matrix.
18. The ophthalmic implant of claim 17 , wherein the one or more therapeutic agents dispersed within the polymer matrix are part of the anterior panel.
19. An ophthalmic implant comprising:
an intraocular lens (IOL) comprising an anterior side, a posterior side opposite the anterior side, a lens, a circumferential side wall circumscribing the lens, and a haptic coupled to and extending outwards from the circumferential side wall; and
a drug delivery device comprising a posterior structure comprising a posterior structure side wall, an anterior structure comprising an anterior structure side wall, a pair of posts joining the posterior structure and the anterior structure, and an aperture bounded by the posterior structure, the anterior structure, and the pair of posts, wherein the haptic is configured to be received within the aperture of the drug delivery device such that: at least a portion of the posterior structure side wall lies adjacent the circumferential side wall of the IOL; and at least a portion of the anterior structure side wall protrudes inward of the circumferential side wall of the IOL on the anterior side of the IOL.
20. The ophthalmic implant of claim 19 , wherein the anterior structure side wall is a panel.